Search This Blog

Tuesday, April 5, 2022

COVID-19 pandemic spurred increase in gig workers, unique jobs

 The workplace in America shifted in 2020 — and two years later, jobs are still offering work-from-home options.

On top of that, many people picked up side hustles throughout the COVID-19 pandemic.

One of these side hustles involves furry friends for one Las Vegas woman.

Anna Riggi of Las Vegas, a single mom of six, started renting her backyard through Sniffspot as an extra source of income. (Ashley Soriano/Fox Business) (Fox News)

She’s one of tens of millions of Americans to pick up a freelance job on the side, and conveniently, it’s right in her backyard.

Anna Riggi's full-time job is caring for her six children.

"I'm a single mom and can always use a little extra income," Rigby said.

Working a traditional office job is out of the question, so she started renting her backyard to dog owners.

"I have had a group birthday party where I've had four dogs here at once. They rented my backyard for a little birthday party. And I thought, ‘Okay,’" Riggi said.

She uses an app called Sniffspot.

"You can think of it like Airbnb for dog parks," said David Adams, Sniffspot's founder.

Sniffspot launched in 2018, and the number of hosts skyrocketed during the pandemic. (Ashley Soriano/Fox Business) (Fox News)

Sniffspot connects hosts with backyards to dog owners who may not have access to one otherwise, or who may prefer privacy.

The company has thousands of hosts in the U.S. and internationally.

It was just two years old when COVID-19 hit.

"I guess in Washington, D.C., they shut down everything, including public dog parks, public parks and there was no option for anyone to get out at all," Adams said. "We just exploded in Washington, D.C., and now Washington, D.C. is one of our biggest markets."

The gig economy exploded — jobs like driving for Uber or Doordash, and in other cases like Anna Riggi, renting her backyard.

"We've in many ways opened up Pandora's Box when it comes to people working from home," said Leith Martin, the executive director of the Troesh Center for Entrepreneurship and Innovation at the University of Nevada-Las Vegas.

"A lot of those people are going to struggle to give up some of that freedom that they had from working at home," Martin said. 

A projected 87 million people will work freelance or gig working jobs by 2028, according to Statista.

"I can set my schedules and what days I want on or off, and it's been nice," Riggi said. "It's nice having a little extra because, you know, I'm a single mom, and it really helps me out."

Sniffspot’s founder says some hosts make over $2,000 a month from the comfort of their own home — or backyard.

https://www.foxbusiness.com/economy/pandemic-spurred-increase-gig-workers

UnitedHealth, Change Healthcare Extend Deal Pact to End of Year

 UnitedHealth Group Inc. and Change Healthcare Inc. on Tuesday said they have extended their merger agreement to Dec. 31 in the wake of the Justice Department's antitrust lawsuit challenging the nearly $8 billion deal.

UnitedHealth early last year agreed to combine its Optum health-services arm with health-technology company Change, but federal regulators in February sued to block the deal, arguing the tie-up would unlawfully reduce competition in markets for commercial insurance and the processing of claims.

UnitedHealth and Change said the challenge is without merit, and that they plan to detail the benefits of the combination to the healthcare system at a two-week trial slated to begin on Aug. 1.

As part of the extension, UnitedHealth will pay a $650 million fee to Change if the companies can't complete the merger due to the court's decision.

https://www.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-14750/news/UnitedHealth-Change-Healthcare-Extend-Deal-Pact-to-End-of-Year-39967059/

Allergan's Twice-Daily Vuity Study Hits Main Endpoint in Presbyopia

 AbbVie Inc.'s Allergan unit on Tuesday said a Phase 3 study of twice-daily use of its Vuity eye drops met the main endpoint in adults with age-related blurry near vision, also known as presbyopia.

Allergan said the study, which met the primary endpoint of improving near vision without compromising distance vision at hour nine on day 14, would form the basis of an application for expanded approval of Vuity that the company plans to file with the U.S. Food and Drug Administration in the second quarter.

The FDA last year approved once-daily use of Vuity as the first and only eye drop to treat age-related blurry near vision in adults.

Allergan, which AbbVie acquired in 2020 in a $63 billion deal, said roughly 128 million people in the U.S. experience presbyopia, which reduces the eye's ability to focus on near objects and usually affects people after age 40.

https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/Allergan-s-Twice-Daily-Vuity-Study-Hits-Main-Endpoint-in-Presbyopia-39970484/

Bristol Myers Squibb's Breyanzi Receives European Commission Marketing Authorization

 Bristol Myers Squibb Co. said the European Commission has approved marketing authorization for Breyanzi, a lymphoma treatment.

The marketing authorization is based on results from a study evaluating Breyanzi in adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, including those with a range of histologies and high-risk disease.

The marketing authorization is applicable in all European Union member states.

https://www.marketscreener.com/quote/stock/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-s-Breyanzi-Receives-European-Commission-Marketing-Authorization-39971617/

COVAX, African Union decline to buy more doses of Moderna's COVID shots

 COVAX, the global project to share COVID-19 vaccines, and the African Union have declined options to buy additional doses of Moderna's shot, as developing nations struggle to allocate supplies.

A spokesperson for Gavi, part of the COVAX alliance, confirmed the news.

The discussions with Moderna are part of "regular decision-making process on exercising options outlined in our advance purchase agreements with manufacturers", the spokesperson said.

Moderna and Gavi have agreements for up to 650 million doses of the company's vaccine to be made available to COVAX participants through 2021 and 2022.

COVAX, also backed by the World Health Organization and the Coalition for Epidemic Preparedness Innovations (CEPI), has picked up pace of supplies after struggling to acquire shots last year.

It has delivered about 1.40 billion doses to 144 countries as of April 1.

As supply and donations ramped up, some poorer nations are facing hurdles such as gaps in cold-chain shortage, vaccine hesitancy and a lack of funds to support distribution networks.

"We are in conversations with manufacturers ... to align with magnitude and timing of country needs," the Gavi spokesperson added.

https://www.marketscreener.com/quote/stock/MODERNA-INC-47437573/news/COVAX-African-Union-decline-to-buy-more-doses-of-Moderna-s-COVID-shots-39971449/

FDA pulls authorization for GSK-Vir's COVID therapy as BA.2 cases rise

 The U.S. health regulator said on Tuesday GlaxoSmithKline and Vir Biotechnology's antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country.

The move by the agency, which had already pulled its authorization for the sotrovimab therapy in much of the U.S. northeast last month, sent shares in Vir Biotechnology 11.5% lower.

The highly contagious BA.2 coronavirus sub-variant is estimated to make up about three of every four COVID-19 cases in the United States, according to the latest government data.

GlaxoSmithKline and Vir have said treatment with sotrovimab retains neutralizing activity against the BA.2 sub-variant, but others, including researchers from Columbia University, disagree.

Vir Biotechnology in a filing with the Securities and Exchange Commission said the two companies were preparing a package of data to support the use of a higher dose of sotrovimab for the Omicron BA.2 sub-variant, which will be shared with regulators globally, reiterating the companies' plan from last month.

Vir still expects to recognize about $1.1 billion in collaboration revenue when sotrovimab doses are delivered in the first half of 2022.

The companies also plan to submit an application for full approval of the drug in the second half of the year, and expect to start two late-stage trials in the second quarter to assess whether sotrovimab can prevent symptomatic COVID-19 infection in immunocompromised patients, Vir said.

GSK spokeswoman Lyndsay Meyer said the company will continue to work with governments and health systems, and ensure ongoing access to sotrovimab.

https://www.marketscreener.com/quote/stock/GLAXOSMITHKLINE-PLC-9590199/news/FDA-pulls-authorization-for-GSK-Vir-s-COVID-therapy-as-BA-2-cases-rise-39972893/

Tenn. Senate Advances Bill To Withhold Funds From Schools Allowing Transgender Athletes To Compete

 by Matt McGregor via The Epoch Times (emphasis ours),

Tennessee legislation that would withhold funding from school districts allowing transgender students to participate in sports passed in the Senate Education Committee on March 29.

If passed into law, Senate Bill 1861 (pdf) would require the commissioner of education to withhold a portion of state education funding if the school refuses to determine the gender of a student participating in sports.

“We passed a bill last year that required boys to play boys and girls to play girls in K–12, and this bill is putting teeth into it,” Rep. John Ragan, a Republican, said on the House floor when speaking about the companion House Bill 1895.

The bill assigns unspecified financial penalties to the Tennessee law passed in 2021 that prohibited males from playing in female sports.

Opposition to the Bill

According to organizations such as the Human Rights Campaign (HRC), one of the largest LGBTQ-advocate organizations, the bill is discriminatory. The organization stated that allowing transgender youth to participate in sports doesn’t disadvantage other athletes.

This bill is only an attempt to continue the conversation to publicly ostracize, demonize, and harm transgender children who only want to play,” HRC said in a press release.

Rep. Gloria Johnson, a Democrat, said of the bill’s passage on Twitter: “Today on the floor we passed another LGBTQ hate bill (HB1895) that takes away school funding based on last year’s ‘solution’ to a problem we don’t have. There is so much hate in this body due to pure ignorance—it’s stunning.”

In response to those who call it a “hate bill,” Ragan told The Epoch Times that those statements are “emotionally-based rhetoric, not based in logic.”

“And I personally don’t hate any of these people,” Ragan said. “But by the same token, the law is the same for everybody. You don’t get a special exemption just because you think you’re not what you are physically.

Quoting from the Enlightenment writer and philosopher Voltaire, Ragan said, “‘Those who can make you believe absurdities can make you commit atrocities.’ And the definition of absurdity in my mind is denying reality.”

Rep. Kent Calfee, a Republican, pointed to the transgender swimmer at the University of Pennsylvania who in March won the 500-yard freestyle race at the NCAA Division 1 women’s championship. Lia Thomas grew up competitively swimming as a male who began taking hormone replacement therapy in 2019, declaring himself a woman in his junior year in college.

That’s totally unfair to people who were born a woman and are competing,” Calfee said.

Another Ragan-sponsored bill, HB 2316, which passed in House and Senate committees, would prohibit males from participating in female sports in higher education.

On March 30—or what has been nationally deemed “Transgender Day of Visibility,” President Joe Biden said transgender Americans continue to be discriminated against as his administration issued a batch of documents promoting transgender surgery and hormone therapy in children.

“In the past year, hundreds of anti-transgender bills in States were proposed across America, most of them targeting transgender kids,” Biden said. “The onslaught has continued this year.  These bills are wrong.”

In January 2021, Biden signed an executive order titled “Preventing and Combating Discrimination on the Basis of Gender Identity or Sexual Orientation.”

On March 31, the U.S. Department of Health and Human Services’ (DHHS) Office of Population Affairs released a document titled “Gender-Affirming Care and Young People,” which endorses gender-reassignment surgery and hormone treatment for minors. On the same day, the Substance Abuse and Mental Health Services Administration’s National Child Traumatic Stress Network (NCTSN), a division of DHHS, released a document titled, “Gender Affirming Care is Trauma-Informed Care,” which promotes surgical procedures for minors.

Providing gender-affirming care is neither child maltreatment nor malpractice,” the NCTSN document states.

It also says there is no scientific research showing negative impacts on a child’s well-being after receiving puberty blockers or what it calls “gender-affirming hormones.”

A Tennessee bill prohibiting transgender procedures in children stalled in the Senate General Subcommittee where it will likely not pass. House Bill 2835, or the Youth Protection Act, would have specifically prohibited a child who hasn’t reached puberty from getting hormone therapy or other gender alterations, such as surgeries, even if parents approve. If they have reached puberty but are still a minor, they must get parental consent.

We have age restrictions on our youth for a number of different reasons that are there to protect them,” Ragan said. “These protections are multifaceted and across the board.”

The bill would have made it illegal to perform procedures that would “facilitate the minor’s desire to present or appear in a manner that is inconsistent with the minor’s sex.”

Scientifically, at a cellular level, one is either male or female,” Ragan said. “There’s no denying that, aside from some genetic malfunctions. But what some have decided is that what’s between their ears should conquer reality. The reality is that’s not true.”

DHHS, NCTSN, and Biden cited mental health issues leading to high suicide rates resulting from what he called transgender discrimination.

Ragan shared a study that argued the opposite (pdf). It examined 324 sex-reassigned persons (191 male-to-females, 133 female-to-males) in Sweden that concluded that people “with transsexualism, after sex reassignment, have considerably higher risks for mortality, suicidal behavior, and psychiatric morbidity than the general population.”

The study defines transsexualism, or gender identity disorder, as a condition in which a person’s gender identity “contradicts his or her bodily sex characteristics.”

The study found “substantially higher rates of overall mortality, death from cardiovascular disease and suicide, suicide attempts, and psychiatric hospitalizations in sex-reassigned transsexual individuals compared to a healthy control population.”

In 2004, the Birmingham University Aggressive Research Intelligence Facility (ARIF) assessed the findings of more than 100 follow-up studies of post-operative transexuals.

ARIF concluded that none of the studies provided “conclusive evidence that gender reassignment is beneficial for patients.”

https://www.zerohedge.com/political/tennessee-senate-advances-bill-withholds-funding-schools-allowing-transgender-athletes